Objective-To assess the use of laboratory tests for genital chlamydial infection in Norway. Design-Questionnaire survey of general practitioners' practice in chlamydial testing, retrospective survey of laboratory records, 1986-91, and prospective study of testing in one laboratory during four weeks. Setting-All 18 microbiological laboratories in Norway (4-2 million population), including one serving all doctors in Vestfold county (0.2 million population). 
Genital chlamydial infestion in women is associated with infertility, chronic abdominal pain, and ectopic pregnancy.' 2 Three quarters of all cases of genital chlamydial infection in women are believed to be asymptomatic.' 4 Hence, in most cases the infection is probably diagnosed through routine testing rather than clinical testing. In Norway most of this testing takes place in general practice as there are only three genitourinary medicine clinics and 60 gynaecologists, who practise privately. Cell culture is regarded as the standard for chlamydial testing.5 The method has a 100% specificity, but a transport time from the general practitioner (GP) to the laboratory of less than 24 hours is crucial for survival of the chlamydias and thus for test sensitivity. For most GPs in Norway this prohibits the use of the method. Enzyme immunoassays (EIAs) detect chlamydial antigens, not viable chlamydias, and are therefore independent of transport times. A recent study in Trondheim, Norway, evaluated against cell culture the performance of two EIAs curently being used in Norway (Chlamydiazyme, Abbot Laboratories; Ideia, Celltech).' A specificity of 95-99% (table 1) agrees with performances observed in several other studies of these assays.56
Norwegian microbiologists have reported that chlamydial tests make up a rapidly increasing share of their laboratories' workload.8 Large scale screening for genital chlamydial infection seems to have been instituted without any official guidelines. The purpose of this study was to assess the present use of testing for chlamydial infection in Norway. I chose to survey GPs directly to obtain an estimate of their routine practice. The laboratories provided the total number of tests performed, the methods used, and the distribution of these tests by sex and age of the patient.
Subjects and methods

SURVEY OF GENERAL PRACTITIONERS
I sent a structured questionnaire to every 10th (n=302) GP on the alphabetical membership list of the Norwegian Medical Association, followed by a reminder two weeks later. The GPs were to indicate if they routinely performed a chlamydial test on "all," "most," "some," or "none" of asymptomatic patients in the following categories: women younger than 25 years at routine pelvic examinations during visits for family planning, young girls at their first pelvic examination, pregnant women at one of their antenatal controls, and men who stated that their female partner had unspecified urogenital complaints. The GPs' routines for treatment of genital chlamydial infections9 and notification of partners'0 have been reported from the same survey.
NATIONWIDE LABORATORY SURVEY
I sent a questionnaire to all the 18 medical microbiological laboratories in Norway, requesting information on the methods they used for chlamydial testing, the number of genital specimens tested, and the number of positive test results from 1986 to 1991. The laboratories were asked to count multiple specimens from the same patients as one specimen.
VESTFOLD CENTRAL LABORATORY STUDY
To obtain the age and sex distribution of the tested patients in all the laboratories would be a formidable task. For simplicity I chose to record these data in a randomly selected four week period in only one laboratory. Vestfold Central Laboratory was chosen because it serves all hospitals and doctors within Vestfold county but no doctor outside the county. Sex and age of the patients who received a chlamydial test were registered by using the laboratory's computerised database of incoming samples. By using census data the distribution of tests could be converted to sex specific and age group specific rates for chlamydial testing. The laboratory used the Chlamydiazyme assay.
ESTIMATES OF FALSE POSITIVE RATES
The predictive value of a positive diagnostic test (positive predictive value, PPV) is related to the prevalence (P) of the condition in the population; the specificity of the test (Sp); and, to a lesser degree, the sensitivity of the test (Sn) by the following equation'':
The false positive rate (FPR) denotes the percentage of the positive test results that are false positive and is given by the equation:
To obtain estimates of PPV and FPR that were independent of the Vestfold survey I used the test performances (Sn and Sp) from the Trondheim study (table 1) and the prevalences (P) of chlamydial infection (as determined by cell culture) in different age 
Discussion
More than 30% of the GPs did not answer the questionnaire. Possibly GPs who seldom diagnose chlamydial infections may not have responded; these GPs would probably do less routine testing resulting in a biased response.
The laboratories were instructed to report tests on only genital specimens and to count multiple specimens from the same patient as one specimen. Some laboratories were unable to do this. However, the survey in the Vestfold laboratory showed that less than 1% of the specimens were non-genital and that less than 5% were multiple specimens.
The prevalence of chlamydial infection in women having a legal abortion is probably higher than in the general female population. Therefore my use of the prevalence of infection in women having an abortion to represent the prevalence in the general population will lead to an underestimation of the false positive rates of the chlamydial tests. The false positive rates presented in Prevalence (%) Relation between positive predictive value, prevalence of infection, and specificity (curves) of test at 90% sensitivity.
Minor influence of sensitivity is shown by curve of 80% sensitivity (broken line) for 96-5% specificity asymptomatic Norwegian women of any age group for chlamydial infection.
The solutions to these problems must include the defining of a national screening policy. Its aims should be to reduce the costs; reduce the number of false positive diagnoses or at least their consequences; and to control the epidemic of chlamydial infections.
A graphical illustration of the relation between test performances, prevalence of infection, and positive predictive value (figure) shows two ways of solving the problem of false positive tests. Firstly, testing could be restricted to populations that have a presumed high prevalence of infection. Then even tests with 95% specificity would be reasonably useful. The populations could be defined not only on the basis of their age but also on other demogaphic or clinical factors. Several investigators have tried to find useful criteria for defining groups that have a high risk of genital chlamydial infection. In the United States age, recent change of partner, cervical friability, and mucopurulent cervicitis are predictors of chlamydial cervicitis." 2 However, cultural differences probably prohibit the usefulness of these predictors in populations other than those from which they were derived.
Restricting testing leads of course to the larger issues of patient care and health policy. By restricting testing, some infected patients would inevitably be missed. These patients may also be victims of pelvic inflammatory disease, with possible reproductive sequelae, and they may also transmit chlamydial infection to others. These questions must be addressed openly. The decisions on screening policy cannot be left to individual GPs.
Secondly, the use of tests with a better specificity could be encouraged. A small increase in specificity would greatly enhance the predictive value of a positive test, especially in populations with a low prevalence of infection (figure). Better tests are now available: for the EIAs confirmatory blocking assays have been marketed,22 and these will increase specificity. However, even a test with a specificity as good as 99-5% will rapidly lose its positive predictive value in populations with a prevalence of infection below 2%.
Finally, every doctor bears a heavy responsibility for understanding the limitations of diagnostic tests in populations with a low prevalence of infection. This understanding is a prerequisite for good care of their patients.
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